Although BSCM surgery has significant associated risks, including perioperative complications, new neurological deficits, and death, most patients have favorable outcomes. Overall, surgery markedly improved the risk of rehemorrhage and related symptoms and should be considered in patients with accessible lesions.
Lumbar interbody fusion involves insertion of a structural graft into an intervertebral disc space to promote bony arthrodesis. It is a well-established surgical strategy for multiple spinal disorders ranging from degenerative conditions to trauma, neoplastic diseases, and deformities requiring correction. Since the inception of lumbar interbody fusion, the most established techniques have been two posterior approaches, the posterior lumbar interbody fusion (PLIF) and the transforaminal lumbar interbody fusion (TLIF). Within the past 15 years, multiple anterolateral approaches to the spine have become widely adopted. These approaches can be performed minimally invasively and spare disruption of the paraspinal muscles and posterior spinal column while enabling wide exposure of the disc space for insertion of interbody grafts much larger than PLIF and TLIF instrumentation. This review highlights three minimally invasive anterolateral approaches: the anterior lumbar interbody fusion (ALIF), the transpsoas lateral lumbar interbody fusion (LLIF), and prepsoas or anterior to the psoas oblique lumbar interbody fusion (OLIF). Relevant topics for discussion and comparison include patient selection, surgical techniques, outcomes, and complications for the three surgical approaches.
The role of Ca 2؉ signaling in triggering hypertrophy was investigated in neonatal rat cardiomyocytes in vitro. We show that an increase in cell size and sarcomere reorganization were elicited by receptor agonists such as Angiotensin II, aldosterone, and norepinephrine and by a small rise in medium KCl concentration, a treatment devoid of direct effects on receptor functions. All these treatments increased the frequency of spontaneous [Ca 2؉ ] transients, caused nuclear translocation of transfected NFAT(GFP), and increased the expression of a NFAT-sensitive reporter gene. There was no increase in Ca 2؉ spark frequency in the whole cell or in the perinuclear region under these conditions. Hypertrophy and NFAT translocation but not the increased frequency of [Ca 2؉ ] transients were inhibited by the calcineurin inhibitor cyclosporine A. Hypertrophy by the different stimuli was insensitive to inhibition of myofilament contraction. We concluded that calcineurin-NFAT can act as integrators of the contractile Ca 2؉ signal, and that they can decode alterations in the frequency even of rapid Ca 2؉ oscillations. C ardiac hypertrophy accompanies many forms of heart pathologies, such as genetic or congenital defects, ischemia, and hypertension. The molecular signaling pathways through which the different hypertrophic stimuli modulate cardiac cell size include mitogen-activated protein kinase, Gp130/Stat3, Calmodulin (CaM)-dependent kinases, and the calcineurin-regulated pathway (1). The latter has recently received much attention, in part because it can be the target of therapeutic intervention with well known drugs. For example, in transgenic mice, it has been demonstrated that overexpression of the Ca 2ϩ -dependent phosphatase calcineurin causes a dramatic increase in the size of the heart, inhibited by cyclosporine A (CsA), a calcineurin blocker (2). Along the same line, overexpression of Cain/Cabin (molecules that associate with the calcineurin and inhibit its activity) attenuate cardiac hypertrophy caused not only by calcineurin overexpression but also by pressure overload or -adrenergic receptor stimulation (3). The effect of CsA on cardiac hypertrophy, however, has led to contradictory results in different model systems (4,5).At the cellular level, cardiomyocyte hypertrophy is characterized by an increase in cell size, enhanced protein synthesis, activation of fetal genes, and cytoskeleton reorganization (4, 5). A number of treatments are known to induce cardiac cell hypertrophy in vitro, including angiotensin II (Ang II) (6), catecholamines (7), endothelin (8), and aldosterone (9). Many, but not all, of these hormones are known to be coupled to alterations in Ca 2ϩ homeostasis. In particular, (i) Ang II (6) and endothelin (10) are coupled to IP 3 generation and Ca 2ϩ mobilization from stores; (ii) catecholamines, in particular through 1 receptors, are known to induce an increase in the frequency and amplitude of Ca 2ϩ spiking in cardiomyocytes (7); and (iii) the mechanism of aldosterone-induced hypertrophy in vit...
Pedicled VBGs can feasibly be applied to posterior spinal arthrodesis from occiput to T12. Patients at high risk for nonunion may benefit from this strategy.
Rationale: Uncoupling protein (UCP)2 is a mitochondrial inner membrane protein that is expressed in mammalian myocardium under normal conditions and upregulated in pathological states such as heart failure. UCP2 is thought to protect cardiomyocytes against oxidative stress by dissipating the mitochondrial proton gradient and mitochondrial membrane potential (⌬⌿ m ), thereby reducing mitochondrial reactive oxygen species generation. However, in apparent conflict with its uncoupling role, UCP2 has also been proposed to be essential for mitochondrial Ca 2؉ uptake, which could have a protective action by stimulating mitochondrial ATP production. Objective: The goal of this study was to better understand the role of myocardial UCP2 by examining the effects of UCP2 on bioenergetics, Ca 2؉ homeostasis, and excitation-contraction coupling in neonatal cardiomyocytes. Methods and Results: Adenoviral-mediated expression of UCP2 caused a mild depression of ⌬⌿ m and increased the basal rate of oxygen consumption but did not affect total cellular ATP levels. Mitochondrial Ca 2؉ uptake was examined in permeabilized cells loaded with the mitochondria-selective Ca 2؉ probe, rhod-2. UCP2 overexpression markedly inhibited mitochondrial Ca 2؉ uptake. Pretreatment with the UCP2-specific inhibitor genipin largely reversed the effects UCP2 expression on mitochondrial Ca 2؉ handling, bioenergetics, and oxygen utilization. Electrically evoked cytosolic Ca 2؉ transients and spontaneous cytosolic Ca 2؉ sparks were examined using fluo-based probes and confocal microscopy in line scan mode. UCP2 overexpression significantly prolonged the decay phase of [Ca 2؉ ] c transients in electrically paced cells, increased [Ca 2؉ ] c spark activity and increased the probability that Ca 2؉ sparks propagated into Ca 2؉ waves. This dysregulation results from a loss of the ability of mitochondria to suppress local Ca 2؉ -induced Ca 2؉ release activity of the sarcoplasmic reticulum. Conclusion: Increases in UCP2 expression that lower ⌬⌿ m and contribute to protection against oxidative stress, also have deleterious effects on beat-to-beat [Ca 2؉ ] c handling and excitation-contraction coupling, which may contribute to the progression of heart disease. (Circ Res. 2010;106:730-738.) Key Words: uncoupling protein-2 Ⅲ mitochondria Ⅲ calcium Ⅲ calcium sparks Ⅲ excitation-contraction coupling I n ventricular myocytes, the majority of the sarcolemmal Ca 2ϩ current comes from voltage-gated L-type Ca 2ϩ channels. These L-type Ca 2ϩ channels are primarily found at the junctions of the sarcolemma with the sarcoplasmic reticulum (SR) where they are coupled to SR Ca 2ϩ -release channels, ryanodine receptors (RyRs), forming junctional complexes. 1 The coupling of RyRs to L-type Ca 2ϩ channels serves to amplify [Ca 2ϩ ] c increases through Ca 2ϩ -induced Ca 2ϩ release (CICR), to meet the threshold needed to initiate cellular contraction.It is well established that mitochondria have a large capacity to accumulate Ca 2ϩ and that mitochondrial Ca 2ϩ ([Ca 2ϩ ] m ...
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.